Cosentyx By Novartis: New Treatment For Hidradenitis Suppurativa

Novartis announces that the European Commission has approved its Cosentyx for use in the EU in adults with moderate to severe active hidradenitis suppurativa who have failed to respond to conventional systemic therapy.

This European approval is based on robust Phase III data showing that Cosentyx provided rapid symptom relief as early as week 4, with response rates continuing to improve for up to one year, with its known safety profile. .

Hidradenitis suppurativa is a chronic inflammatory disease of the skin resulting in painful and potentially disfiguring abscesses. Around 200,000 people in Europe are currently living with moderate to severe stages of the disease.

This article is originally published on boursorama.com

Electric Scooter XElectric Scooter XElectric Scooter XElectric Scooter X

Subscribe

Related articles

War in Ukraine: Russian army maintains pressure in Kramatorsk region

The Russian army is not letting up the pressure...

War in Ukraine must not become ‘new normal’: UN

“There has been a very clear intensification of the...

Iran exchanges prisoners with Sweden, eight Europeans remain captive

Iran and Sweden announced a prisoner swap on Saturday,...

Iran, Sweden complete prisoner swap

Iran and Sweden announced a prisoner swap on Saturday,...
Electric Scooter X